ITIF-迈向更健康的未来_GLP-1的变革潜力（英）-2025.8._36页_887kb

Obesity Epidemic Summary

Scale and Impact

• Prevalence: 42.4% of U.S. adults are obese, with rates rising significantly since the early 2000s. Childhood obesity also increases, with nearly one in five youth affected.
• Economic Toll: Obesity costs the U.S. economy $452.6 billion annually (2.3% of GDP), driven by direct medical expenses, lost productivity, and sector-specific burdens like reduced airline fuel efficiency.
• Health Consequences: Obesity drives increased risks of diabetes, cardiovascular disease, and premature death, reducing life expectancy by 2.1 years in the U.S.

GLP-1 Receptor Agonists: A Breakthrough

• Effectiveness: GLP-1 drugs (e.g., Ozempic, Wegovy) promote ~15% weight loss and improve metabolic health, with additional benefits like cardiovascular protection and reduced hospitalizations.
• Broader Impacts: Beyond weight loss, GLP-1s show promise in treating neurological disorders (e.g., Alzheimer’s) and reducing substance use behaviors, offering multifaceted health and economic benefits.

Economic and Policy Considerations

• Economic Benefits: GLP-1 therapies could boost U.S. GDP by 0.4% and save $400 billion annually through reduced healthcare costs and improved workforce productivity.
• Policy Recommendations:
  • Support basic research and integrate GLP-1s into healthcare systems.
  • Expand Medicare coverage, considering dynamic scoring to account for broader economic impacts.
  • Address access barriers and promote societal-level interventions, including workplace accommodations and public health initiatives.

Challenges

• Adherence & Access: Long-term adherence may be hindered by side effects and delivery methods; rising costs limit access, especially for low-income populations.
• System-Wide Impact: Obesity strains industries beyond healthcare, such as transportation (due to fuel inefficiency) and the military, influencing readiness and operational costs.

Conclusion

Obesity is a complex health and economic crisis requiring systemic solutions. GLP-1 therapies represent a transformative medical advancement, with innovative policies and investments poised to address its drivers, improve population health, and enhance economic resilience.